The efficacy of different doses of etoricoxib Vs. naproxen 1000mg for ankylosing spondylitis .
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis
BMC Musculoskelet Disord. 2016 Oct 13;17(1):4261015 patients with ankylosing spondylitis were randomized initially to 6 weeks of either etoricoxib 60mg daily, etoricoxib 90mg daily, or naproxen 1000mg daily. After 6 weeks, patients of the etoricoxib 60mg group were re-randomized to either continue on etoricoxib 60mg daily for 20 weeks or increase to etoricoxib 90mg daily for 20 weeks. Within the first 6 weeks, both etoricoxib 60mg and etoricoxib 90mg demonstrated noninferior efficacy in reducing spinal pain when compared to naproxen 1000mg. At 26 weeks, a similar degree of reduction in spinal pain was observed among all groups. Etoricoxib did not appear to increase the risk of treatment-related adverse events compared to naproxen.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
